{"url_path":"/sec/coya/8-k/2026-05-12/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1835022/0001193125-26-218198-index.html","accession_number":"0001193125-26-218198","cik":"0001835022","ticker":"COYA","issuer_name":"Coya Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1835022/0001193125-26-218198-index.html","primary_entity_key":"0001835022","primary_entity_name":"Coya Therapeutics, Inc."},"word_count":29,"has_tables":true,"body_markdown":"Item 8.01. Other Events.\n\n \n\nOn May 11, 2026, the U.S. Food and Drug Administration granted Fast Track Designation to COYA 302 for the treatment of Amyotrophic Lateral Sclerosis (ALS)."}